$210 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 51 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | Celgene Corp | $17,398,000 | +15.6% | 253,522 | +33.8% | 8.27% | +43.1% |
| ILMN | Buy | ILLUMINA INC | $14,522,000 | +15.5% | 51,600 | +14.7% | 6.90% | +43.0% |
| INCY | Buy | Incyte Corp | $10,593,000 | +25.5% | 200,000 | +58.8% | 5.04% | +55.3% |
| ARRY | Buy | Array Biopharma Inc | $9,844,000 | -15.5% | 844,500 | +21.6% | 4.68% | +4.6% |
| EXEL | Buy | Exelixis Inc | $9,574,000 | +0.1% | 704,534 | +58.5% | 4.55% | +23.9% |
| STML | Buy | Stemline Therapeutics Inc | $7,459,000 | -5.1% | 585,930 | +18.9% | 3.54% | +17.4% |
| AERI | Buy | Aerie Pharmaceuticals Inc | $5,908,000 | +492.0% | 125,179 | +747.0% | 2.81% | +633.2% |
| PBYI | Buy | Puma Biotechnology Inc | $5,074,000 | +85.7% | 144,300 | +211.7% | 2.41% | +129.9% |
| ZGNX | New | Zogenix Inc | $4,184,000 | – | 110,000 | +100.0% | 1.99% | – |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $3,543,000 | -2.2% | 52,800 | +43.5% | 1.68% | +21.0% |
| JAZZ | Buy | Jazz Pharmaceuticals PLC | $2,785,000 | -0.2% | 21,600 | +33.3% | 1.32% | +23.5% |
| STRO | New | SUTRO BIOPHARMA INC | $1,686,000 | – | 146,653 | +100.0% | 0.80% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $1,035,000 | – | 65,000 | +100.0% | 0.49% | – |
| CRVS | Buy | Corvus Pharmaceuticals Inc | $710,000 | -20.4% | 108,000 | +32.8% | 0.34% | -1.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.